作者: José Belderbos , Lon Uitterhoeve , Nico van Zandwijk , Huub Belderbos , Patrick Rodrigus
DOI: 10.1016/J.EJCA.2006.09.005
关键词: Carcinoma 、 Nuclear medicine 、 Gemcitabine 、 Radiation therapy 、 Cisplatin 、 Pneumonitis 、 Lung cancer 、 Survival analysis 、 Internal medicine 、 Gastroenterology 、 Respiratory disease 、 Medicine
摘要: A randomised phase III study was performed comparing sequential (S) and concurrent (C) chemo-radiotherapy (CRT) in non-small cell lung cancer (NSCLC) patients. Methods : One hundred fifty-eight patients were to receive two courses of Gemcitabine (1250 mg/m2 days 1, 8) Cisplatin (75 day 2) prior to, or daily low-dose (6 mg/m2) with radiotherapy, consisting 24 fractions 2.75 Gy 32 days, a total dose 66 Gy. Results Acute haematological toxicity grade 3/4 more pronounced the (30% versus 6%), oesophagitis frequent arm (5% 14%). Late 3 4% (S C), pneumonitis 14% 18% (C). Because poor power no significant differences median survival (MS), overall (OS) progression-free (PFS) could be detected. MS 16.2 16.5 months, 2-year OS 34% 39% (C), 3-year 22% Conclusion Radiotherapy given concurrently after Gemcitabine/Cisplatin well tolerated. Due early closure conclusions can reached on relative merits; both arms showed good OS.